The use of advanced organ imaging in radiotherapy of the upper-abdomen for kidney response assessment and treatment optimisation

In radiotherapy treatment of upper-abdominal cancer patients, can response assessment with functional single photon emission computed tomography (SPECT) imaging be used to reduce kidney toxicity and improve the radiotherapy?

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12609000322235

Acronym

RAPRASI

Enrollment

Registered

2009-05-21

Start date

2011-01-03

Completion date

2017-12-31

Last updated

2021-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Radiotherapy to the upper-abdomen is challenging due to the presence of the kidneys. We will couple single photon emission computed tomography (SPECT) with X-ray computed tomography (CT) to determine the effect of radiotherapy on kidney function. Combining the imaging with information on delivered radiation dose will enable us to examine the complex interactions between radiation and kidney response in order to develop unique models for optimizing radiation dose delivery and predicting outcomes.

Interventions

External beam radiotherapy for pancreatic or stomach cancer to 54 Gy in 30 daily (excluding weekends) fractions. Sequential SPECT imaging with 99m-Technetium-dimercaptosuccinic acid (99Tc-DMSA) at commencement of radiotherapy (0 weeks) and at 4, 12, 26, 52 and 78 weeks

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patient has histologically/cytologically proven adenocarcinoma of the pancreas or upper-gastrointestinal (GI) tract. Metastatic disease status excluded on whole body computed tomography (CT) series. Locoregional staging of primary disease has been undertaken with dual phase (arterial and portal) spiral CT. Adequate bone marrow function: Haemoglobin (Hb)>10, White Blood Cells (WBC)>3.5 (Neutrophilis>1.5), Platelets >100 Serum creatinine <150 Patient has given written informed consent. Performance status is East Coast Oncology Group (ECOG) grade 0, 1 or 2

Exclusion criteria

Major co-morbid illnesses that, in the opinion of the investigator, would jeopardise the likely completion of the treatment program. Patients with significant loss of bodyweight (>15% weight loss since diagnosis). Treatment with any previous cytotoxic chemotherapy for the malignancy. Previous abdominal radiotherapy.

Outcome results